Ocular Findings in Medullary Nephrocalcinosis
The most important ocular findings in medullary nephrocalcinosis occur specifically with CLDN19 mutations causing familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), and include chorioretinal atrophy, severe myopia, nystagmus, and retinitis pigmentosa.
Primary Etiology: CLDN19 Mutations
The key distinction in medullary nephrocalcinosis is that ocular involvement is pathognomonic for CLDN19 gene mutations, not CLDN16 mutations, despite both causing the same renal phenotype 1, 2, 3, 4. This represents a critical diagnostic clue when evaluating patients with medullary nephrocalcinosis.
Specific Ocular Manifestations
The documented eye findings in CLDN19-related FHHNC include:
- Chorioretinal atrophy (bilateral) - most characteristic finding 2
- Severe myopia - frequently present 3
- Retinitis pigmentosa - disturbed retinal organization and development 3
- Horizontal nystagmus (bilateral) 3
- Visual impairment - though notably, some patients may have subtle findings without frank visual loss 4
Pathophysiological Mechanism
The ocular involvement stems from claudin-19's role as a tight junction protein that is expressed not only in the thick ascending limb of Henle but also in ocular tissues 1, 3. This shared molecular pathway explains the reno-ocular syndrome pattern, where mutations affecting CLDN19 disrupt both renal magnesium/calcium handling and ocular structural integrity 5.
Clinical Recognition Pattern
When evaluating a patient with medullary nephrocalcinosis, the presence of ANY ocular abnormality should immediately prompt genetic testing for CLDN19 mutations 4. The clinical presentation typically includes:
- Consanguineous parents (autosomal recessive inheritance)
- History of neonatal hypomagnesemic convulsions
- Hypomagnesemia refractory to oral supplementation (<0.65 mmol/L)
- Hypercalciuria (partly thiazide-sensitive)
- Progressive renal decline
Important Caveat
Ocular manifestations can be subtle and may not cause visual symptoms initially 4. Therefore, all patients with FHHNC should undergo formal ophthalmologic examination even in the absence of visual complaints, as early detection may influence genetic counseling and management strategies.
Other Etiologies Without Ocular Findings
Medullary nephrocalcinosis from other causes—including primary hyperoxaluria 6, CLDN16 mutations, medullary sponge kidney 7, and metabolic disorders—do not typically present with ocular findings. The exception is primary hyperoxaluria with systemic oxalosis in advanced disease, though this represents a different pathophysiologic mechanism 6.
Diagnostic Algorithm
When encountering medullary nephrocalcinosis:
- Perform ophthalmologic examination looking specifically for chorioretinal changes, myopia, and nystagmus
- If ocular findings present: Order CLDN19 genetic testing as first-line
- If ocular findings absent: Consider CLDN16 mutations, primary hyperoxaluria, or other metabolic causes
- Measure serum magnesium and 24-hour urine calcium/magnesium to support FHHNC diagnosis 6
The presence or absence of ocular involvement fundamentally narrows the differential diagnosis and directs genetic testing strategy 8.